Glutamatergic signaling in cellular transformation
Authors:
- 20 February 2012
- journal article
- review article
- Published by Wiley in Pigment Cell & Melanoma Research
- Vol. 25 (3) , 331-342
Abstract
Summary: The role of the glutamatergic system in cancer cell homeostasis has expanded exponentially over the last decade. Once thought to participate only in synaptic transmission and neuronal excitability, the presence of functional glutamate receptors has since been demonstrated in peripheral tissues. Most notable is the implication of glutamate receptors in the pathophysiology of various human malignancies. We previously described the oncogenic properties of metabotropic glutamate receptor 1 (Grm1), a G‐protein‐coupled receptor in melanoma development in vivo. TG‐3, a transgenic mouse line, developed spontaneous melanoma with 100% penetrance in the absence of any known stimuli. Stable Grm1‐mouse melanocytic clones display transformed phenotypes in vitro and were aggressively tumorigenic in vivo. Recent reports from other groups implicate two additional members of the metabotropic glutamate receptor family in melanomagenesis, overexpression of mGluR5 and activating mutations in GRM3. These findings highlight a previously underappreciated link between the glutamate signaling pathway and oncogenesis in melanoma biology, raising exciting possibilities in elucidating mechanisms in melanocyte transformation and exploring glutamate receptors as novel therapeutic targets. Here we further consider the potential mechanisms by which glutamate receptors can function as an oncogene leading to malignant transformation.Keywords
This publication has 86 references indexed in Scilit:
- Acquired Resistance to BRAF Inhibitors Mediated by a RAF Kinase Switch in Melanoma Can Be Overcome by Cotargeting MEK and IGF-1R/PI3KCancer Cell, 2010
- COT drives resistance to RAF inhibition through MAP kinase pathway reactivationNature, 2010
- Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulationNature, 2010
- Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanomaNature, 2010
- Targeting Mitochondrial Glutaminase Activity Inhibits Oncogenic TransformationCancer Cell, 2010
- Glutamine addiction: a new therapeutic target in cancerTrends in Biochemical Sciences, 2010
- Activating mutations of the GNAQ gene: a frequent event in primary melanocytic neoplasms of the central nervous systemActa Neuropathologica, 2009
- Frequent somatic mutations of GNAQ in uveal melanoma and blue naeviNature, 2008
- BRAF mutation predicts sensitivity to MEK inhibitionNature, 2005
- Apoptosis and increased generation of reactive oxygen species in Down's syndrome neurons in vitroNature, 1995